INmune Bio (INMB) News Today $8.86 +0.56 (+6.75%) Closing price 04:00 PM EasternExtended Trading$8.85 -0.01 (-0.17%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period INmune Bio (INMB) Projected to Post Quarterly Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comINmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's ResultsMarch 18, 2025 | seekingalpha.comINmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by AnalystsShares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toMarch 10, 2025 | marketbeat.comELEVAI Labs Inc. Ends License Agreement with INmuneMarch 3, 2025 | tipranks.comINmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%February 20, 2025 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Short Interest UpdateINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 5,510,000 shares, an increase of 9.5% from the January 15th total of 5,030,000 shares. Based on an average daily volume of 330,500 shares, the days-to-cover ratio is presently 16.7 days.February 17, 2025 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Buy" by BrokeragesINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has received a consensus rating of "Buy" from the five brokerages that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. TheFebruary 14, 2025 | marketbeat.comINmune Bio (NASDAQ:INMB) Given New $30.00 Price Target at Maxim GroupMaxim Group boosted their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday.February 14, 2025 | marketbeat.comINmune Bio price target raised to $30 from $22 at MaximFebruary 13, 2025 | markets.businessinsider.comINmune Bio, Inc.: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate CancerFebruary 13, 2025 | finanznachrichten.deRaymond James raises INmune Bio stock target to $23February 12, 2025 | msn.comINmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate CancerFebruary 12, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)February 11, 2025 | markets.businessinsider.comScotiabank raises INmune Bio stock target to $23 on new therapyFebruary 11, 2025 | msn.comINmune Bio price target raised to $23 from $22 at ScotiabankFebruary 11, 2025 | markets.businessinsider.comINmune Bio (NASDAQ:INMB) Price Target Raised to $23.00Scotiabank increased their price target on INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Tuesday.February 11, 2025 | marketbeat.comINmune Bio's CORDStrom shows promise in RDEB treatmentFebruary 10, 2025 | msn.comINmune Bio announces plans to submit FDA BLA for CORDStromFebruary 10, 2025 | markets.businessinsider.comINmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)February 10, 2025 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in JanuaryINmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 4,280,000 shares, an increase of 7.0% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 229,900 shares, the short-interest ratio is presently 18.6 days.February 4, 2025 | marketbeat.comWhy INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comINmune Bio (NASDAQ:INMB) Rating Increased to Strong-Buy at RODMAN&RENSHAWRODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a report on Tuesday.January 29, 2025 | marketbeat.comINmune Bio expands INKmune trial in prostate cancer to veteransJanuary 28, 2025 | markets.businessinsider.comINmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28, 2025 | markets.businessinsider.comRodman & Renshaw sets INmune Bio stock Buy rating, $23 targetJanuary 28, 2025 | msn.comBTIG maintains INmune Bio stock Buy rating and $21 targetJanuary 28, 2025 | msn.comINmune Bio (NASDAQ:INMB) Now Covered by Analysts at Rodman & RenshawRodman & Renshaw assumed coverage on INmune Bio in a research note on Tuesday. They issued a "buy" rating and a $23.00 price objective on the stock.January 28, 2025 | marketbeat.comINmune Bio treatment of epidermolysis bullosa receives FDA orphan designationJanuary 7, 2025 | markets.businessinsider.comINmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025January 2, 2025 | seekingalpha.comINmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial DangersDecember 30, 2024 | seekingalpha.comINmune Bio Inc. Completes Repayment of Silicon Valley Bank DebtDecember 10, 2024 | markets.businessinsider.comOmniScience and INmune Bio Partner for Alzheimer’s TrialDecember 5, 2024 | finance.yahoo.comINmune Bio, OmniScience partner to accelerate trial with VivoDecember 5, 2024 | markets.businessinsider.comOmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control TowerDecember 4, 2024 | finance.yahoo.comOmniScience And INmune Bio Unveil Partnership To Drive Faster Decision-Making In Alzheimer's TrialDecember 4, 2024 | markets.businessinsider.comOmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control TowerDecember 4, 2024 | globenewswire.comINmune Bio (NASDAQ:INMB) Trading 1.7% Higher - Should You Buy?INmune Bio (NASDAQ:INMB) Trading 1.7% Higher - Here's What HappenedNovember 27, 2024 | marketbeat.comINmune Bio, Inc.: INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's DiseaseNovember 14, 2024 | finanznachrichten.deInmune Bio’s Innovative Alzheimer’s Treatment Approach Earns ‘Buy’ Rating from AnalystNovember 14, 2024 | markets.businessinsider.comINmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's DiseaseNovember 14, 2024 | markets.businessinsider.comINmune Bio announces enrollment of 208 patients in Phase 2 trial of early ADNovember 14, 2024 | markets.businessinsider.comINmune Bio holds an investor and analyst webinarNovember 8, 2024 | markets.businessinsider.comInmune Bio’s Promising Pipeline and Financial Stability Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comINmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)November 4, 2024 | finance.yahoo.comINmune Bio (NASDAQ:INMB) Announces Quarterly Earnings ResultsINmune Bio (NASDAQ:INMB - Get Free Report) posted its earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 121.57% and a negative net margin of 26,333.59%. During the same period last year, the business earned ($0.48) EPS.November 3, 2024 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comInmune Bio Reports Increased Losses Amid Financing EffortsNovember 2, 2024 | markets.businessinsider.comBuy Rating on Inmune Bio: Promising EMACC Endpoint and Innovative XPro Drug in Alzheimer’s TreatmentNovember 2, 2024 | markets.businessinsider.comINmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...November 2, 2024 | finance.yahoo.comINmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business UpdateOctober 31, 2024 | globenewswire.com Remove Ads Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Media Mentions By Week INMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼0.880.68▲Average Medical News Sentiment INMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼22▲INMB Articles Average Week Remove Ads Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gyre Therapeutics News Today Oculis News Today Replimune Group News Today Cogent Biosciences News Today Day One Biopharmaceuticals News Today Evolus News Today Avadel Pharmaceuticals News Today Anavex Life Sciences News Today Pharvaris News Today Avid Bioservices News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INMB Stock Free INMB Stock Alerts